ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome

Abstract

Aim: This study investigated the ATP binding cassette (ABC) transporter (ABCA1, ABCB1, ABCB3, ABCC2 and ABCG2) expression in high grade serous ovarian cancer (HGSOC) tissues, cell lines and primary cells to determine their potential relationship with acquired chemotherapy resistance and patient outcome.

Methods: ABC transporter mRNA and protein expression (ABCA1, ABCB1, ABCB3, ABCC2 and ABCG2) was assessed in publicly available datasets and in a tissue microarray (TMA) cohort of HGSOC at diagnosis, respectively. ABC transporter mRNA expression was also assessed in chemosensitive ovarian cancer cell lines (OVCAR-5 and CaOV3) versus matching cell lines with acquired carboplatin resistance and in primary HGSOC cells from patients with chemosensitive disease at diagnosis (n = 10) as well as patients with acquired chemotherapy resistance at relapse (n = 6). The effects of the ABCA1 inhibitor apabetalone in carboplatin-sensitive and -resistant cell lines were also investigated.

Results: High ABCA1 mRNA and protein expression was found to be significantly associated with poor patient outcome. ABCA1 mRNA and protein levels were significantly increased in ovarian cancer cell lines (OVCAR-5 CBPR and CaOV3 CBPR) with acquired carboplatin resistance. ABCA1 mRNA was significantly increased in primary HGSOC cells obtained from patients with acquired chemotherapy resistance. Apabetalone treatment reduced ABCA1 protein expression and increased the sensitivity of both parental and carboplatin-resistant ovarian cancer cells to carboplatin.

Conclusion: These results suggest that inhibiting ABCA1 transporter may be useful in overcoming acquired chemotherapy resistance and improving outcome for patients with HGSOC.

Keywords

HGSOC / chemotherapy resistance / ABC transporter / ABCA1 / ABCB1 / TAP2 / ABCB3 / ABCC2 / ABCG2 / apabetalone

References

[1] Siegel RL,Jemal A.Cancer statistics, 2020..CA Cancer J Clin2020;70:7-30

[2] 2019 AIHW. Cancer in Australia 2019. In. Cancer series Canberra: AIHW: Australian Institute of Health and Welfare 2019; 2019. Available from https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2019/data [Last accessed on 19 Feb 2021]

[3] Helleman J,Burger C,Berns EM.Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs..Int J Biochem Cell Biol2010;42:25-30

[4] Chien J,Landen C.Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment..Front Oncol2013;3:251 PMCID:PMC3781360

[5] Etemadmoghadam D,Beroukhim R.Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas..Clin Cancer Res2009;15:1417-27 PMCID:PMC2670486

[6] Bukowski K,Kontek R.Mechanisms of Multidrug Resistance in Cancer Chemotherapy..Int J Mol Sci2020;21: PMCID:PMC7247559

[7] Ween MP,Oehler MK.The role of ABC transporters in ovarian cancer progression and chemoresistance..Crit Rev Oncol Hematol2015;96:220-56

[8] Cerovska E,Vaclavikova R.The role of membrane transporters in ovarian cancer chemoresistance and prognosis..Expert Opin Drug Metab Toxicol2017;13:741-53

[9] Yvan-Charvet L,Tall AR.Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses..Arterioscler Thromb Vasc Biol2010;30:139-43 PMCID:PMC2812788

[10] Aguirre-Portoles C,Reglero G.ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin-1-dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone..Mol Oncol2018;12:1735-52 PMCID:PMC6166002

[11] Hedditch EL,Russell AJ.ABCA transporter gene expression and poor outcome in epithelial ovarian cancer..J Natl Cancer Inst2014;106:dju149 PMCID:PMC4110473

[12] Schimanski S,Treeck O.Expression of the lipid transporters ABCA3 and ABCA1 is diminished in human breast cancer tissue..Horm Metab Res2010;42:102-9

[13] Raspollini MR,Villanucci A,Taddei GL.Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival..Int J Gynecol Cancer2005;15:255-60

[14] Yakirevich E,Naroditsky I.Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas..Gynecol Oncol2006;100:152-9

[15] Chen H,Wang L.Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression..Br J Cancer2009;101:432-40 PMCID:PMC2720231

[16] Sedlakova I,Caltova K.Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer..Int J Gynecol Cancer2015;25:236-43

[17] Arts HJ,de Vries EG.Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma..Clin Cancer Res1999;5:2798-805

[18] Huang X,Komai K.Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer..Gynecol Oncol2004;93:287-91

[19] Auner V,Oskay-Oezcelik G,Speiser P.ABC transporter gene expression in benign and malignant ovarian tissue..Gynecol Oncol2010;117:198-201

[20] Han LY,Urbauer DL.HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma..Clin Cancer Res2008;14:3372-9 PMCID:PMC3426216

[21] Leffers N,Mokhova AA.Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer..Gynecol Oncol2009;113:256-63

[22] Surowiak P,Kaplenko I.ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome..Clin Cancer Res2006;12:7149-58

[23] Kim H,No JH,Jeon HW.Prognostic Value of Biomarkers Related to Drug Resistance in Patients with Advanced Epithelial Ovarian Cancer..Anticancer Res2012;32:589-94

[24] Ohishi Y,Uchiumi T.ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma..Clin Cancer Res2002;8:3767-75

[25] Guminski AD,Chiew YE.MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma..Gynecol Oncol2006;100:239-46

[26] Zhang W,Wang Y,Meng L.Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway..Oncol Lett2018;15:5155-60 PMCID:PMC5840666

[27] Zhang S,Chan MW.Identification and characterization of ovarian cancer-initiating cells from primary human tumors..Cancer Res2008;68:4311-20 PMCID:PMC2553722

[28] Gyorffy B,Szallasi Z.Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients..Endoc Relat Cancer2012;19:197-208

[29] Ricciardelli C,Pyragius CE.Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance..Oncotarget2017;8:17819-32 PMCID:PMC5392289

[30] Allahverdian S,McManus BM,Francis GA.Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis..Circulation2014;129:1551-9

[31] Margaryan NV,Salkeni MA.The Stem Cell Phenotype of Aggressive Breast Cancer Cells..Cancers (Basel)2019;11:340 PMCID:PMC6468512

[32] Chu TM,Lin TH.Characterization of a new monoclonal antibody F4 detecting cell surface epitope and P-glycoprotein in drug-resistant human tumor cell lines..Hybridoma1993;12:417-29

[33] Surowiak P,Kaplenko I.ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome..Clin Cancer Res2006;12:7149-58

[34] Maliepaard M,Faneyte IF.Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues..Cancer Res2001;61:3458-64

[35] Brunham LR,Pape TD.Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels..Circ Res2006;99:672-4

[36] Andersen V,Knudsen LA.Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology..World J Gastroenterol2015;21:11862-76 PMCID:PMC4631984

[37] Drozdzik M,Lapczuk J.Protein Abundance of Clinically Relevant Drug Transporters in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens..Clin Pharmacol Ther2019;105:1204-12

[38] Mutch DM,Fiaux M.Regional variations in ABC transporter expression along the mouse intestinal tract..Physiol Genomics2004;17:11-20

[39] Jedlitschky G,Kroemer HK.Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition..Expert Opin Drug Metab Toxicol2006;2:351-66

[40] Feng Z,Ju XZ.Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)..J Ovarian Res2017;10:7 PMCID:PMC5264293

[41] Ricciardelli C,Cheruvu S.Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation..Clin Exp Metastasis2015;32:441-55

[42] Ricciardelli C,Lokman NA,Pyragius CE.Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer..BMC Cancer2013;13:476 PMCID:PMC3852938

[43] Chou TC.Drug combination studies and their synergy quantification using the Chou-Talalay method..Cancer Res2010;70:440-6

[44] Ween MP,Hoffmann P,Ricciardelli C.Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells..Int J Cancer2011;128:1570-84

[45] Shukla S,Suresh V.Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges..Expert Opin Drug Metab Toxicol2008;4:205-23

[46] Martin C,Mistry P,Charlton P.The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein..Br J Pharmacol1999;128:403-11 PMCID:PMC1571648

[47] Liu KJ,Su XD.Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo..Int J Cancer2013;132:224-35 PMCID:PMC3459133

[48] Oram JF.ABCA1. The gatekeeper for eliminating excess tissue cholesterol..J Lipid Res2001;42:1173-9

[49] Wang N.Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux..Arterioscler Thromb Vasc Biol2003;23:1178-84

[50] Bi DP,Zhang XY,Xu JY.MiR-183 functions as an oncogene by targeting ABCA1 in colon cancer..Oncol Rep2016;35:2873-9

[51] Chou JL,Shay J.Hypermethylation of the TGF-beta target, ABCA1 is associated with poor prognosis in ovarian cancer patients..Clin Epigenetics2015;7:1 PMCID:PMC4307187

[52] Lee BH,Robinet P.Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1..Cancer Res2013;73:1211-8 PMCID:PMC3563867

[53] Smith B.Anticancer activity of the cholesterol exporter ABCA1 gene..Cell Rep2012;2:580-90 PMCID:PMC3462268

[54] Vargas T,Herranz J.ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients..Oncotarget2015;6:7348-63 PMCID:PMC4466690

[55] Sekine Y,Stonik JA.High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism..Mol Cancer Res2010;8:1284-94 PMCID:PMC2941551

[56] Oiso S,Nakazaki R.Factors involved in the cisplatin resistance of KCP4 human epidermoid carcinoma cells..Oncol Rep2014;31:719-26

[57] Akhter MZ,Kumar V.Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM⁺ CD45⁺ phenotype..Oncogene2018;37:2089-103

[58] Chrusciel M,Wolczynski S,Rahman NA.Extragonadal FSHR Expression and Function-Is It Real?.Front Endocrinol (Lausanne)2019;10:32 PMCID:PMC6369633

[59] Nouaille S,Finoux AL,Girbal L.The stability of an mRNA is influenced by its concentration: a potential physical mechanism to regulate gene expression..Nucleic Acids Res2017;45:11711-24 PMCID:PMC5714132

[60] Rahman M.Predicting the protein half-life in tissue from its cellular properties..PLoS One2017;12:e0180428 PMCID:PMC5515413

[61] Johnatty SE,Gao B.ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas..Gynecol Oncol2013;131:8-14 PMCID:PMC3795832

[62] Duan Z,Seiden MV.Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells..Mol Cancer Ther2004;3:833-8

[63] Januchowski R,Sujka-Kordowska P,Zabel M.MDR Gene Expression Analysis of Six Drug-Resistant Ovarian Cancer Cell Lines..Biomed Res Int2013;2013:241763-11 PMCID:PMC3591129

[64] Kiguchi K,Suzuki N.Characteristic expression of globotriaosyl ceramide in human ovarian carcinoma-derived cells with anticancer drug resistance..Cancer Sci2006;97:1321-6

[65] Ho EA,Allen C.Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors..J Control Release2007;117:20-7

[66] Veneroni S,Daidone MG,Villa R.Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers..Eur J Cancer1994;30A:1002-7

[67] Bourhis J,Riou G,Gottesman MM.Expression of a human multidrug resistance gene in ovarian carcinomas..Cancer Res1989;49:5062-5

[68] Holzmayer TA,Von Hoff DD.Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas..J Natl Cancer Inst1992;84:1486-91

[69] Patch AM,Etemadmoghadam D.Whole-genome characterization of chemoresistant ovarian cancer..Nature2015;521:489-94

[70] Hlavac V,Vaclavikova R.The expression profile of ATP-binding cassette transporter genes in breast carcinoma..Pharmacogenomics2013;14:515-29

[71] Arts HJ,de Vries EG.Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma..Clin Cancer Res1999;5:2798-805

[72] Kamazawa S,Kanamori Y.Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer..Gynecol Oncol2002;86:171-6

[73] Ohishi Y,Uchiumi T.ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma..Clin Cancer Res2002;8:3767-75

[74] Obata H,Quan J,Tanaka K.Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer..Anticancer Res2006;26:2227-32

[75] Marsh S,King CR,McLeod HL.Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer..J Clin Oncol2007;25:4528-35

[76] Sparreboom A,Burger H.Effect of ABCG2 genotype on the oral bioavailability of topotecan..Cancer Biol Ther2005;4:650-8

[77] Tian C,Darcy KM.Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study..Gynecol Oncol2012;124:575-81 PMCID:PMC3278512

[78] He QZ,Wang K.Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas..Cell Physiol Biochem2014;33:173-84

[79] Januchowski R,Zaorska K.Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines..J Ovarian Res2016;9:65 PMCID:PMC5069986

[80] Maliepaard M,de Jong LA.Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line..Cancer Res1999;59:4559-63

[81] Jia P,Li F.Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells..Int J Gynecol Cancer2005;15:1042-8

[82] Nicholls SJ,Johansson JO.Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease..Am J Cardiovasc Drugs2018;18:109-15

[83] Ray KK,Buhr KA.Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial..JAMA2020;323:1565-73 PMCID:PMC7101505

[84] Gilham D,Tsujikawa LM.RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease..Atherosclerosis2016;247:48-57

[85] Haarhaus M,Nicholls SJ.Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease..Atherosclerosis2019;290:59-65

[86] Jahagirdar R,Azhar S.A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice..Atherosclerosis2014;236:91-100

[87] Wasiak S,Halliday C.Benefit of Apabetalone on Plasma Proteins in Renal Disease..Kidney Int Rep2018;3:711-21 PMCID:PMC5976837